165 LUDLOW AVENUE, NORTHVALE, NJ
Market cap: $523.6M (12/18/2025)
Price: $0.49
Financial Results, Reg. FD
Amended material disclosure
Receives FDA Approval for Generic Requip XL®
To Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
To Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
To Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Q2
Q3
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence